SCHEMBL2572017

SCHEMBL2572017

CC(C)(C)OC(=O)NCc1ccc(-c2ccccc2)c(OCCCNC(=O)OCc2ccccc2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.49
L3MBTL1 Q9Y468 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
POLB P06746 2/20 0.46
GPR55 Q9Y2T6 1/20 0.46
KLK7 P49862 1/20 0.46
KLK5 Q9Y337 1/20 0.46
RECQL P46063 1/20 0.46
MAPK1 P28482 1/20 0.45
HTT P42858 1/20 0.45
PDCD1 Q15116 1/20 0.45
CD274 Q9NZQ7 1/20 0.45
NTSR1 P30989 1/20 0.45
SYK P43405 1/20 0.45
KDM4E B2RXH2 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
LMNA P02545 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2572286 0.88 L3MBTL1 (0.50) MAPTL3MBTL1HTTCD274LMNA
SCHEMBL2572703 0.87 KDM4E (0.50) L3MBTL1MEN1KMT2APDCD1CD274
SCHEMBL2568606 0.85 ADRB2 (0.48) L3MBTL1MEN1KMT2AHTTPDCD1
SCHEMBL2572124 0.85 HDAC1 (0.47) L3MBTL1MEN1KMT2AHTTPDCD1
SCHEMBL2571458 0.85 KDM4E (0.51) L3MBTL1MEN1KMT2AHTTPDCD1
SCHEMBL2803491 0.85 KDM4E (0.47) L3MBTL1MEN1KMT2AHTTPDCD1
SCHEMBL2572715 0.84 MEN1 (0.41) MAPTMEN1KMT2APOLBGPR55
SCHEMBL2571914 0.84 MAPT (0.50) MAPTL3MBTL1MEN1KMT2APOLB
SCHEMBL2570501 0.83 CCR6 (0.41) MAPTMEN1KMT2APOLBGPR55
SCHEMBL2809615 0.83 CCR6 (0.46) MAPTL3MBTL1MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1813623-B1 PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF KISSEI PHARMACEUTICAL (JP) 2011-11-09 EP disclosed
US-20100249054-A9 PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2010-09-30 US disclosed
US-7795236-B2 Purine nucleoside derivative modified in 8-position and medical use thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2010-09-14 US disclosed
US-20070179115-A1 Purinenucleoside derivative modified in 8-position and medical use thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1813623-A1 PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2007-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249054-A9 PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF NUDT1, PNP, SLC28A2 MAPT 3754/4885L3MBTL1 483/4885MEN1 3310/4885
US-20070179115-A1 Purinenucleoside derivative modified in 8-position and medical use thereof NUDT1, SLC28A2, PNP MAPT 3869/4885L3MBTL1 342/4885MEN1 3540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.